Objective: We performed a meta-analysis to assess the efficacy and safety of T-DXd in the treatment of HER2-expressing solid tumours.
Methods: We systematically searched PubMed, Web of Science, Embase and the Cochrane Library and collected studies published before March 17, 2023, on T-DXd for HER2-expressing tumours for a meta-analysis. We performed a subgroup analysis based on the different cancer types and the doses used.
Results: There were 11 studies including 1349 HER2-expressing patients in this meta-analysis. The pooled ORR was 47.91%, and the pooled DCR was 87.01%. The mPFS and mOS combined were 9.63 and 10.71 months, respectively. The most common adverse reactions in grades 1-2 were decreased appetite (49.3%) and vomiting (43.0%). The netropemia (31.2%) and leukopenia (31.2%) were the most common grade 3 and higher adverse reactions. Subgroup analysis showed that breast cancer had the best ORR and DCR, with 66.96 and 96.52%, respectively.
Conclusions: Overall, the efficacy of T-DXd in treating HER2-expressing solid tumours is encouraging, especially breast and non-small cell lung cancers, and has an acceptable safety profile. However, concerns remain about potentially serious treatment adverse events (e.g. interstitial lung disease/pneumonia). More well-designed, large-scale randomized controlled trials are needed to demonstrate our study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jjco/hyad036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a Novel Prosthetic Click-Linker for Radioiodination of Antibody-Based Radiopharmaceuticals with High Stability and Specificity.
Mol Pharm
January 2025
Division of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
Article Synopsis
- Radioiodine is used in nuclear medicine for diagnosing and treating diseases, primarily through two methods of radioiodination: direct and indirect.
- The newly developed compound 3-[I]IBTTT offers a high radiochemical yield and purity while simplifying purification processes, overcoming issues present in traditional methods.
- This compound demonstrated effective HER2-specific binding in tumor imaging with minimal thyroid uptake, making it a promising option for targeting HER2-positive cancers.
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Clin Cancer Res
December 2024
Department of Medicine, Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington.
Purpose: This multicenter phase Ib study investigated trastuzumab deruxtecan (T-DXd) plus nivolumab in patients with HER2-expressing metastatic breast cancer (mBC) and metastatic urothelial cancer (mUC).
Patients And Methods: Part 1 determined the recommended dose for expansion of T-DXd plus nivolumab. Part 2 evaluated efficacy and safety; the primary endpoint was confirmed objective response rate by independent central review.
Influence of PEGylation on HER2-targeting retro A9 peptide analogue.
Nucl Med Biol
December 2024
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India; Homi Bhabha National Institute, Mumbai, India. Electronic address:
Article Synopsis
- * The study examined a modified A9 peptide, [Lu]Lu-DOTA-PEG-rL-A9, which includes a long polyethylene glycol (PEG) chain to enhance its effectiveness and circulation time.
- * Results showed that the PEGylated peptide had better cellular uptake and tumor targeting in HER2-expressing cells and in tumor models, indicating improved specificity and potential for better imaging of metastatic breast cancer compared to the non-PEGylated version.
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.
Adv Ther
November 2024
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Article Synopsis
- The DESTINY-PanTumor02 study investigated trastuzumab deruxtecan (T-DXd) for treating HER2-expressing solid tumors in patients who had prior treatment, focusing on IHC 3+ and 2+ tumors across seven cancer types.
- Results showed a higher objective response rate (ORR) in patients with IHC 3+ tumors (51.4%) compared to those with IHC 2+ tumors (26.5%), with median durations of response of 14.2 months and 9.8 months, respectively.
- The study concluded that T-DXd provides significant clinical benefit, especially for patients with HER2 IHC 3+ tumors, reinforcing its therapeutic potential
Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors.
Immunohorizons
August 2024
Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX.
The fertilized chicken egg chorioallantoic membrane (CAM), a highly vascularized membrane nourishing the developing embryo, also supports rapid growth of three-dimensional vascularized tumors from engrafted cells and tumor explants. Because murine xenograft models suffer limitations of time, cost, and scalability, we propose CAM tumors as a rapid, efficient screening tool for assessing anti-tumor efficacy of chimeric Ag receptor (CAR) T cells against solid tumors. We tested the efficacy of human epidermal growth factor receptor 2 (HER2)-specific CAR T cells against luminescent, HER2-expressing (FaDu, SCC-47) or HER2-negative (MDA-MB-468) CAM-engrafted tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!